Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 20/20 | 0.67 |
| ▸ | GRIN1 | Q05586 | 16/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29550496 | 1.00 | GRIN2B (0.67) | GRIN2BGRIN1CYP2C9KCNH2 | |
| SCHEMBL22775639 | 0.95 | GRIN2B (0.61) | GRIN2BGRIN1CYP2C9KCNH2 | |
| SCHEMBL29550361 | 0.95 | GRIN2B (0.61) | GRIN2BGRIN1CYP2C9KCNH2 | |
| SCHEMBL22775595 | 0.93 | GRIN2B (0.73) | GRIN2BGRIN1CYP2C9KCNH2 | |
| SCHEMBL29550486 | 0.93 | GRIN2B (0.73) | GRIN2BGRIN1CYP2C9KCNH2 | |
| Trifluoroacetic Acid SCHEMBL29550144 | 0.90 | GRIN2B (0.70) | GRIN2BGRIN1CYP2C9KCNH2 | |
| SCHEMBL22775294 | 0.87 | GRIN2B (0.63) | GRIN2BGRIN1CYP2C9KCNH2 | |
| SCHEMBL29550191 | 0.87 | GRIN2B (0.63) | GRIN2BGRIN1CYP2C9KCNH2 | |
| SCHEMBL22802738 | 0.87 | GRIN2B (0.62) | GRIN2BGRIN1CYP2C9KCNH2 | |
| SCHEMBL29550434 | 0.87 | GRIN2B (0.62) | GRIN2BGRIN1CYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151006-A1 | SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-18 | — | — | US | disclosed |
| US-20230151006-A1 | SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-18 | — | — | US | disclosed |
| US-20210017168-A1 | SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-01-21 | — | — | US | disclosed |
| WO-2020249792-A1 | SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151006-A1 | SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR | GRIN2B, GRIN2A, GRIN3A | GRIN2B 1/4885GRIN1 5/4885CYP2C9 2559/4885 |
| US-20210017168-A1 | SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN3A | GRIN2B 1/4885GRIN1 5/4885CYP2C9 2601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.